The Tarrytown, New York-based company said it had profit of $12.81 per share. Earnings, adjusted for one-time gains and costs, were $12.89 per share. The results exceeded Wall Street expectations. The ...

On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Regeneron's Lynozyfic ...

U.S. sales of EYLEA HD and EYLEA, treatments for eye conditions like wet age-related macular degeneration, decreased 25% in ...

Regeneron Pharmaceuticals, Inc. (REGN) reported second-quarter 2025 adjusted earnings per share (EPS) of $12.89, which ...

Q2 2025 earnings call. Learn about AMVUTTRA's strong launch, revenue growth, updated guidance & future outlook.